ETHZilla Aims to Raise $350M to Grow Ether Holdings and Boost Yield Strategy
According to CEO McAndrew Rudisill, the company’s strategy involves deploying Ether (ETH) into income-generating assets within the Ethereum network, such as layer-2 protocols and tokenized real-world assets. Rudisill emphasized, “We believe our business model is highly scalable, with significant fixed operational leverage and recurring positive cash flow.”
This shift reflects a broader trend among digital asset companies seeking to actively participate in the ecosystem, moving beyond merely holding crypto assets towards yield generation—a dynamic that could fuel a new DeFi summer, as noted by industry executives.
### ETHZilla Already Profiting from Ecosystem Participation
The company has accrued approximately $1.5 million in unnamed tokens from its strategic investments within the Ethereum ecosystem. ETHZilla’s financial disclosures reveal ongoing deployment of capital across various protocols that support innovation, network growth, and diversified yield opportunities.
Previously, the firm raised $156.5 million through convertible bonds. Combining this with the latest capital, ETHZilla now manages over $506 million in assets. If the entire $350 million is used to buy more ETH, the firm could acquire an additional 120,000 tokens, supplementing its existing stash of around 102,000 ETH valued at over $428 million.
### ETHZilla’s Growing Role in Ethereum Treasury Holdings
Formerly known as Life Sciences Corp, a Nasdaq-listed biotech firm, the company rebranded as ETHZilla in July to focus on crypto and Ether investments. It ranks as the eighth-largest Ether treasury holder among 69 entities, which collectively own over 5.25 million ETH worth more than $22 billion—approximately 4.25% of the circulating supply.
Leading Ether holders include Tom Lee’s BitMine Immersion Technologies with 2.4 million ETH and Sharplink Gaming with 838,000 tokens.
### From Biotech to Blockchain: Stock Performance
Originally launching as a biotech company in 2016, Life Sciences went public in 2020 but experienced a steep decline, with its stock collapsing over 99% across five years due to limited revenue, ongoing losses, and dilution.
However, recent performance shows a modest recovery, with a 31% increase for the year and a peak in August at $10.70.
https://www.cryptobreaking.com/ethzilla-aims-to-raise-350m/
You may also like
Leave a Reply